AF
NTLA icon

Allworth Financial’s Intellia Therapeutics NTLA Stock Holding History

Allworth Financial’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.8K Sell
3,241
-351
-10% -$4.91K ﹤0.01% 2398
2026
Q1 		$46K Buy
3,592
+1,858
+107% +$23.7K ﹤0.01% 2382
2025
Q4 		$15.6K Buy
1,734
+750
+76% +$10.3K ﹤0.01% 2970
2025
Q3 		$17K Buy
984
+12
+1% +$148 ﹤0.01% 2806
2025
Q2 		$9.12K Buy
972
+390
+67% +$3.2K ﹤0.01% 2941
2025
Q1 		$4.76K Buy
582
+426
+273% +$4.3K ﹤0.01% 2785
2024
Q4 		$1.72K Buy
156
+94
+152% +$1.47K ﹤0.01% 3206
2024
Q3 		$1.27K Sell
62
-76
-55% -$1.75K ﹤0.01% 3137
2024
Q2 		$3.46K Sell
138
-694
-83% -$16.5K ﹤0.01% 2682
2024
Q1 		$22.9K Buy
832
+139
+20% +$3.86K ﹤0.01% 1696
2023
Q4 		$21.1K Buy
693
+670
+2,913% +$19.3K ﹤0.01% 1623
2023
Q3 		$728 Buy
23
+4
+21% +$155 ﹤0.01% 2943
2023
Q2 		$775 Sell
19
-5
-21% -$203 ﹤0.01% 2806
2023
Q1 		$895 Buy
+24
New +$941 ﹤0.01% 2707
2022
Q4 		– Sell
-33
Closed -$2K – 3136
2022
Q3 		$2K Buy
33
+21
+175% +$1.3K ﹤0.01% 2187
2022
Q2 		$1K Buy
+12
New +$609 ﹤0.01% 2207

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Allworth Financial's NTLA Position: Q2 2026 in Review

Allworth Financial reduced its Intellia Therapeutics (NTLA) stake by 9.8% in Q2 2026, selling an estimated $4.91K and leaving 3,241 shares worth $54.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2398.

Allworth Financial first reported a position in NTLA in Q2 2022 and has held it in 16 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Allworth Financial held 3,241 shares of Intellia Therapeutics worth $54.8K as of Q2 2026.
  • Allworth Financial sold 351 Intellia Therapeutics shares in Q2 2026, an estimated $4.91K.
  • Intellia Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #2398 holding.
  • Allworth Financial first reported a position in Intellia Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.